Cargando…

The Role of the Key Differentially Mutated Gene FGFR3 in the Immune Microenvironment of Bladder Cancer

The tumor microenvironment (TME) has been a major focus of research in recent years as a crucial factor in the development and progression of bladder cancer. Unfortunately, the precise composition of TME, particularly the immunological and stromal components, remains unknown. In this work, we downlo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Jun, Zhan, Yan, Li, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391163/ https://www.ncbi.nlm.nih.gov/pubmed/35991125 http://dx.doi.org/10.1155/2022/7952706

Ejemplares similares

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
por: Komura, Kazumasa, et al.
Publicado: (2023)

Significance of the FGFR3 mutation in Chinese patients with bladder cancer
por: Hao, Lanxiang, et al.
Publicado: (2023)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
por: Foth, Mona, et al.
Publicado: (2018)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer
por: Zhang, Zhao, et al.
Publicado: (2020)

A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
por: Neuzillet, Yann, et al.
Publicado: (2012)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

FGFR(3S249C) mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells
por: Xie, Xina, et al.
Publicado: (2019)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
por: Kompier, Lucie C., et al.
Publicado: (2010)

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
por: Yang, Zhao, et al.
Publicado: (2018)

K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder
por: Ahmad, Imran, et al.
Publicado: (2011)

Expression of FGFR3 Protein and Gene Amplification in Urinary Bladder Lesions in Relation to Schistosomiasis
por: Hammam, Olfat, et al.
Publicado: (2017)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Prevalence of Mutations in the FGFR3 Gene in Individuals with Idiopathic Short Stature
por: Mamada, Mitsukazu, et al.
Publicado: (2006)

Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images
por: Velmahos, Constantine S., et al.
Publicado: (2021)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing
por: Millholland, John M, et al.
Publicado: (2012)

ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer
por: di Martino, Erica, et al.
Publicado: (2019)

Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer
por: Li, Faping, et al.
Publicado: (2020)

New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors
por: Szklener, Katarzyna, et al.
Publicado: (2022)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus
por: Miranda, Ludmilla Queirós, et al.
Publicado: (2013)

In silico analysis of the immune microenvironment in bladder cancer
por: Zhang, Ye, et al.
Publicado: (2020)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

A key role of GARP in the immune suppressive tumor microenvironment
por: Hahn, Susanne A., et al.
Publicado: (2016)

Drug-sensitive FGFR3 mutations in lung adenocarcinoma
por: Chandrani, P., et al.
Publicado: (2017)

Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence
por: Monteiro, Camila Ribeiro de Arruda, et al.
Publicado: (2022)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy
por: Cao, Wei, et al.
Publicado: (2017)

Deciphering role of FGFR signalling pathway in pancreatic cancer
por: Kang, Xiaodiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cl9dlsvhu9dq2glseaab7qikk8